stockrow
Saturday 7 November 2026
Export CLDI’s income statement to Excel — free account
Calidi Biotherapeutics, Inc.
CLDI Healthcare Biotechnology
Calidi Biotherapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $45,000.00.
- EPS
- +90.8%
- Free cash flow
- +11.2%
- Total debt
- −7.87%
Quarter to June 2026, against a year earlier
0.70
0.02
+2.94%
Follow CLDI
Alert me
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
5.60 | 9.59 | 1.95 | 0.37 | 1.06 |
Total current assets |
6.26 | 10.23 | 4.30 | 0.79 | 1.48 |
Property, Plant, Equpment (Net) |
0.78 | 0.87 | 1.27 | 0.89 | — |
Long-Term Investments |
— | — | — | — | 230.00 |
Long-term assets (Other) |
0.14 | 0.15 | 0.37 | 0.73 | 0.28 |
Total non-current assets |
2.60 | 3.96 | 5.72 | 1.81 | 230.29 |
Total Assets |
8.86 | 14.18 | 10.02 | 2.60 | 231.77 |
Notes Payable |
— | 3.18 | 0.81 | 4.43 | — |
Accounts Payable |
0.61 | 2.07 | 2.88 | 2.27 | 0.06 |
Accrued Expenses |
1.81 | 2.34 | 5.43 | 5.35 | 0.35 |
Current Part of Debt |
— | — | — | 1.00 | — |
Current Part of Capital Lease |
0.11 | 0.07 | 0.08 | 0.07 | — |
Other current liabilities |
— | 0.64 | — | 29.83 | — |
Total current liabilities |
3.94 | 9.50 | 10.23 | 42.99 | 0.41 |
Long Term Debt (Total) |
0.77 | 0.75 | 2.28 | 0.14 | — |
Liabilities (Preferred Stock) |
— | — | — | 9.60 | — |
Non-current Liabilities (Other) |
0.12 | 0.13 | 2.71 | 43.52 | 246.05 |
Total non-current liabilities |
1.16 | 2.72 | 8.02 | 10.05 | 246.05 |
Total liabilities |
5.10 | 12.21 | 18.25 | 53.04 | 246.46 |
Additional Paid In Capital |
145.39 | 123.28 | 91.38 | 19.93 | — |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
(141.62) | (121.71) | (99.57) | (70.36) | (14.69) |
Common Equity (Total) |
3.76 | 1.97 | (8.23) | (50.44) | (14.69) |
Shareholders Equity (Total) |
3.76 | 1.97 | (8.23) | (50.44) | (14.69) |
Shareholders Equity and Liabilities (Total) |
8.86 | 14.18 | 10.02 | 2.60 | 231.77 |
Shares (Common) |
0.45 | 0.11 | 0.02 | 0.00 | 0.00 |
Shareholders Equity (Tangible) |
3.76 | 1.97 | (8.23) | (50.44) | (14.69) |
Net Debt |
(4.83) | (8.85) | 0.33 | 0.77 | (1.06) |
Total Debt |
0.77 | 0.75 | 2.28 | 1.14 | — |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 26 Oct 2026